Phadia, a leading name in the field of allergy and autoimmune diagnostics, is headquartered in the Czech Republic (CZ). Founded in 2000, the company has established itself as a key player in the global diagnostics industry, with a strong presence in Europe, North America, and Asia. Phadia is renowned for its innovative products, including the ImmunoCAP system, which offers precise and reliable testing for allergies and autoimmune diseases. This unique technology sets Phadia apart, enabling healthcare professionals to deliver accurate diagnoses and tailored treatment plans. With a commitment to advancing diagnostic solutions, Phadia has achieved significant milestones, including numerous certifications and partnerships that enhance its market position. The company continues to lead the way in improving patient outcomes through cutting-edge diagnostic tools and a focus on research and development.
How does Phadia's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Phadia's score of 56 is higher than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Phadia, headquartered in the Czech Republic (CZ), currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Thermo Fisher Scientific Inc., which influences its climate commitments and reporting practices. Phadia's climate initiatives are aligned with those of its parent company, Thermo Fisher Scientific Inc. This includes adherence to the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP). However, specific reduction targets or achievements for Phadia have not been disclosed. As part of its corporate family, Phadia is expected to follow the sustainability strategies and climate pledges set forth by Thermo Fisher Scientific Inc., which may include commitments to reduce greenhouse gas emissions across various scopes. Nonetheless, without specific data or targets available for Phadia, the details of their individual climate commitments remain vague.
Access structured emissions data, company-specific emission factors, and source documents
2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|
Scope 1 | 321,190,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 486,151,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 3 | - | - | - | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Phadia is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.